Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Claritas Pharmaceuticals Inc V.CLAS.H

Alternate Symbol(s):  CLAZF

Claritas Pharmaceuticals, Inc., formerly Kalytera Therapeutics Inc, is a biotechnology company that is focused on developing R-107 for the treatment of vaccine-resistant coronavirus disease (COVID) strains. The Company’s products in development include R-107 for coronavirus disease and Viral Infections, R-107 and Vaccines, and CLA-1816 for treatment of pain. R-107 is designed to defeat COVID viruses on contact. R-107 targets the Achilles heel of COVID, the spike protein on the surface of the virus. R-107 releases nitric oxide, which attaches to a specific amino acid on the spike protein, thereby disabling the spike protein. The CLA-1816 provides effective pain reduction, without the risks of addiction or respiratory suppression that exist with opioid analgesics. CLA-1816 strongly binds with and activates the alpha3 glycine pain receptor in the spine. The Company has leased a laboratory, office, and archival space in Beverly, Massachusetts.


TSXV:CLAS.H - Post by User

Comment by Chritterson Aug 19, 2021 1:27pm
118 Views
Post# 33731164

RE:The slow process to success, part 3

RE:The slow process to success, part 3Whats your Thoughts now Amazighit?

Amazigh wrote: It 

Reminder for the ones that still are invested in CLAS.
Probably Monday or Tuesday start of NR after NR. Which of the NR's hereunder will be first? I bet it will be the PP. A couple of millions would be great to do the phase I and phase II studies. And if we have a PP for a couple of millions and is filled immediately or very fast that means there are institutional investors involved. The fun can starts


Reasons, in my opinion,  why the SP will be $6-$10 end of October / beginning of November.

First of all because of the reasons mentioned in part 2, to summarize CLAS will start releasing NR after NR:

 
-beginning with PP, filled by institutional investors
-Followed by the refund from Australia of $700,000-$900,000
-Announcement of Phase I
-Start of Phase I
-finish of cohort 1, start of cohort 2
-finish of cohort 2, start of cohort 3
-finish of cohort 3, start of cohort 4
-finish of Phase I, evaluation of the study
-other findings, other news releases
 
These releases will support and increase the SP in a timely fashion.
Next to the releases which actually are the fundament of the value of the company you'll have the following aspects of trading on a stock market that influence the price of stock extremely:

 
-The float is very low (35 million shares at the moment), this results in a quick rise in stock price when there are good news and high volumes of trading
 
-I think we don’t have to be troubled by penny flippers, who are a pain in the .ss, keeping the price of a stock low.
 
-Now we are in the teens and especially when we’re above $1 we will see another kind of investors: institutional investors, people with big pockets, so people that can spend $10K-$50K or more on one stock.
 
-We probably will have a short squeeze, getting rid of Anson and other shorters
 
-The most important thing that will result in getting us that high is actually getting back the confidence in CLAS, so the belief that CLAS could actually succeed and become a real Research and Development company that makes a profit. At this moment the confidence among investors is very very low and the SP is reflecting this lack of confidence. The SP at this moment should, in my opinion, be around $1-$1.50, but because investors do not believe in CLAS anymore, thinking we relive the KLY era all again, the SP is at $0.50. Once people see the NR’s coming one after the other and SP rises confidence will be back. You’ll see that the pessimist and bashers of now becoming pumpers. You know them, and keep an eye on them, and you’ll see that they will become the greatest believers in CLAS. LOL!!
 
-Another also important thing is greed and anticipation of good things coming when we have enough money to start a Phase II (the PP will take care of that) and we start and finish the different cohorts of Phase I. The investors will want to have CLAS shares before Phase II starts because a company X could be interested in buying in before phase II starts, or CLAS could get funding, etc. So people want to be early in the game otherwise they will miss SP jumps/spikes because CLAS is halted and is too late to jump in. There will be a lot of demand for CLAS shares and that also will result in an SP rise.
 
Actually, the $6-$10 level is modest in my opinion


<< Previous
Bullboard Posts
Next >>